To explore associations between specific treatments for intraepithelial or early invasive cervical lesions and adverse pregnancy outcomes.
(Obstet Gynecol 2016;0:1-9) DOI: 10.1097/AOG.0000000000001777 C ervical cancer screening aims at detecting and treating precursor lesions before progression to invasive cancer. Well-organized programs with appropriate management of precursor lesions have produced a profound decrease in incidence and mortality of cervical cancer. [1] [2] [3] Treated women are generally of reproductive age, 4 and concern has been raised about the consequences for future fertility and adverse pregnancy outcomes.
Women treated for cervical intraepithelial neoplasia (CIN) have increased risk in future pregnancies of perinatal mortality, preterm deliveries, low birth weight and other adverse pregnancy outcomes. [5] [6] [7] [8] [9] A registry-based Norwegian study from 2008 found that conization increased the risk of preterm delivery, especially for those delivering at earlier gestational ages. 10 However, the treatment method used could not be identified in the individual woman. A later U.K. cohort study reported the risk of preterm birth after CIN treatment to be considerably less than previously reported. 11 However, detailed data on treatment were again unavailable. Phase II of this study showed a twofold increased risk of preterm birth in women with larger excisions. The depth of tissue excised and not the number of treatments influenced risk. 12 Another publication from this study suggested that a woman remained at higher risk of preterm birth throughout her reproductive life once she had a deep treatment (15 mm or greater). 13 In this population-based cohort study, we aimed to explore the association between treatment for intraepithelial or early invasive cervical lesions and adverse pregnancy outcomes. We also aimed to examine the effect of time from treatment to delivery, the amount of tissue excised, and the morphology of the lesions.
MATERIALS AND METHODS
Every resident in Norway is assigned a unique personal identification number used in all administrative and medical registries, making accurate record linkage possible.
The Medical Birth Registry of Norway is a population-based registry containing information on all births in Norway since 1967 (2.8 million births), except most induced abortions. The registry is based on compulsory notification of every pregnancy, from 16 completed weeks of gestation onward, and includes demographic information on the parents, extensive information on maternal health (before and during pregnancy), length of pregnancy, delivery as well as information on the neonate (including birth defects and other adverse pregnancy outcomes). 14 The Cancer Registry of Norway, established in 1951, contains mandatorily reported information on all new cancer cases and certain precancerous lesions. Information from clinical notifications, pathology notifications, and death certificates are the main reporting sources, providing information about site, histologic type, and stage of disease. 15 The Norwegian cervical cancer screening program, run by the cancer registry, receives mandatory reports from pathology and microbiology laboratories and keeps complete records of all Pap test results, histology specimens, and human papillomavirus (HPV) tests. Individual screening data are recorded in four databases: the Cytology Register, the Histology Register, the HPV Test Register, and the CIN Register, the last holding follow-up and treatment data. 16 The Histology and CIN registries are routinely linked to check for missing pathology listings. SNOMED, with some local adaptions, is used for classification (cytology and histology). 17 Since 1997, the CIN Register has recorded individual information on treatment proceduresexcisional (cold knife conization, needle diathermy excision, laser conization, loop electrosurgical excision procedure [LEEP] , radiowaves) and ablative (laser vaporization, cryotherapy) treatments. Time from first treatment to delivery was divided into four categories; less than 2, 2-3, 4-5, and 6 or more years. Information on cone size (weight or volume) was available for 37% of treatments. Amount of tissue excised before delivery was included in the analyses; 1-2, 3-4, and 5 g or greater and 1-4, 5-19, and 20 mL or greater, respectively. In analyses on treatment modalities, only the first treatment was included.
Adverse pregnancy outcomes included preterm birth (birth after at least 22 and before 37 completed weeks of gestation), small for gestational age (those 10% having the lowest weight compared with newborns of the same sex and gestational week; restricted to those of 22 completed weeks of gestation or greater), cesarean delivery (emergency and planned), spontaneous abortion (pregnancy lasting less than 22 completed weeks of gestation), stillbirth (fetus with pregnancy length of 22 completed weeks of gestation or greater and dying before birth), and perinatal mortality (newborns with pregnancy length of 22 completed weeks of gestation or greater and dying within the first 7 days after birth). 18 Preterm deliveries were divided into three categories; 22-27, 28-32, and 33-36 completed weeks of gestation.
Data on potential confounders (maternal age at delivery, parity, marital status, smoking, and previous preterm deliveries) were obtained from the birth registry. Information on maternal country of origin, screening history (Pap tests taken 3.5 years before delivery), and education was obtained from Statistics Norway, the Cytology Register, and the Norwegian National Education Database, respectively.
All women with singleton births in Norway during 1998-2014 (n5545,243) constituted our study cohort. Singleton births (N5943,321) in these women constituted our units of analyses (excluding induced abortions). Only singleton births were included as a result of the association between plurality and preterm birth. Altogether 34,655 plural births, 2,549 births in women with previous cancer, and 126 births in women treated during pregnancy were excluded from the analyses (Fig. 1) .
Hazard ratios (HRs) with 95% confidence intervals (CIs) of adverse pregnancy outcomes (except small for gestational age) were estimated using Cox regression models with gestational day as the time variable. For small for gestational age, relative risks with 95% CIs were estimated using log-binomial regression. Maternal age at delivery (younger than 25, 25- We used robust estimation of variances to account for correlations between births in the same woman. Tests for linear trend over continuous time since treatment and for continuous amount of excised tissue were conducted among births in women treated before delivery. Also, tests for linear trend for amount of excised tissue for the different types of excisional treatments by calendar year were conducted. Statistical tests were two-sided.
To compare pregnancy outcomes before to pregnancy outcome after treatment in the same women, we performed a conditional logistic regression analysis and included only the births closest in time to the treatment (both before and after). Only births in women with births both before and after treatment were included.
The data were analyzed using IBM SPSS Statistics 22 and Stata/IC 14.0. The study was approved by the Regional Committee for Medical and Health Research Ethics of Western Norway.
RESULTS
During 1998-2014, 9,554 (1.0%) of singleton births in Norway occurred in women treated for cervical lesions before delivery. Altogether 195 births occurred in women treated two or three times, of which 67 occurred in women treated with more than one method. Births after treatment were more common in older women (mean age at delivery 32.1 and 29.6 years for those with and without treatment), women of higher parity, women who smoked daily, who were of Norwegian descent, and with higher education (Table 1) . Approximately 50% of women with births after treatment had abnormal Pap test results (cytology diagnosis of atypical squamous cells of undetermined significance or more severe) in the 3.5-year period before delivery. Mean time between treatment and childbirth was 4.3 years (range 0.4-16 years).
Almost 72% of treatments were in women younger than age 30 years (mean age at treatment 27.9 years) ( Table 2 ). Most lesions were classified as CIN 2-3 (95%) and only 2.5% as adenocarcinoma in situ. The majority of lesions (99%) were treated with excisional procedures, the most common being LEEP (46%) and laser conization (38%). However, the treatment method changed over time. During 1998-2000, most lesions (64%) were treated with laser conization; during 2011-2013, most lesions (81%) were treated with LEEP.
The proportions of adverse pregnancy outcomes are displayed in Table 3 . There was a larger proportion experiencing preterm births among women treated before childbirth compared with those not treated (9.7 compared with 5.3%; HR 1.8, 95% CI 1.7-2.0; Table 4 ). This association was significant for excisional procedures overall (9.7 compared with 5.3%; HR 1.8, 95% CI 1.7-2.0) and strongest for cold knife (13 compared with 5.3%; HR 2.6, 95% CI 1.3-5.3) and laser conization (12 compared with 5.3%; HR 2.3, 95% CI 2.0-2.5). The HR was larger for more severe prematurity, being 2.6 (0.9 compared with 0.3%; 95% CI 2.0-3.4) for delivery at 22-27 weeks of gestation (Fig. 2) . Furthermore, there was a decreasing period effect in the strength of association of treatment and preterm birth (HR 0.95 per year, 95% CI 0.93-0.97).
There was also a positive association of treatment before pregnancy and spontaneous abortion (0.5 compared with 0.2%; HR 2.5, 95% CI 1.7-3.7; Table 4 ), and the highest HRs were seen for laser conization (0.6 compared with 0.2%; HR 3.0, 95% CI 1.8-5.3) and LEEP (0.4 compared with 0.2%; HR 2.3, 95% CI 1.3-4.0). In women treated with laser conization, the HRs of stillbirth (0.6 compared with 0.4%; HR 1.8, 95% CI 1.1-2.9) and perinatal mortality (0.8 compared with 0.5; HR 1.9, 95% CI 1.3-2.9) were elevated as well. There was no change in HR of preterm birth (P trend 5.9) or spontaneous abortion (P trend 5.1) with time from treatment to delivery. Table 5 gives the median weight and volume of tissue removed for different types of excisional treatment by time period. Only for laser conization, less amount (weight) of tissue was removed with time. In subanalyses, we found increased HRs of preterm birth with increasing weight of tissue excised (P trend 5.008) ( Table 6 ).
The overall risk estimates for cesarean delivery were close to unity (Table 4) . However, when examining planned and emergency cesarean delivery separately, there was an increased HR of emergency cesarean delivery (9.5 compared with 8.8%; HR 1.2, 95% CI 1.1-1.3).
The HR of preterm birth in women treated for CIN 3 compared with CIN 2 was close to unity (9.6 compared with 9.5%; HR 1.0, 95% CI 0.8-1.3). Also for spontaneous abortion no significant association was found (0.4 compared with 0.8%; HR 0.6, 95% CI 0.2-1.3).
Restricting the analyses to those with abnormal Pap test results 3.5 years before delivery, the HRs of preterm birth and spontaneous abortion were 1.8 (11 compared with 6.4%; 95% CI 1.6-2.0) and 2.5 (0.5 compared with 0.2%; 95% CI 1.4-4.5) in women Unauthorized reproduction of this article is prohibited.
treated before childbirth compared with those not treated. Including only births in women with births both before and after treatment gave a crude odds ratio of 2.2 (95% CI 1.7-2.9) for preterm birth after treatment.
DISCUSSION
In this study, treatment with major excisional procedures, including LEEP, was associated with increased risks of preterm birth and spontaneous abortion. The association of preterm birth was strongest at early gestational ages and for those with the largest amount of tissue excised. Among the study strengths is the populationbased cohort design with information on treatment methods for cervical lesions and adverse pregnancy outcomes from national registries. Treatment information was registered before and independent of birth registry data, thus eliminating recall and reporting biases. The CIN Register has more than 80% ascertainment of treatments. 4 All private gynecologists performing conizations do not routinely send treatment notifications to the cancer registry. These women may be at lower risk of adverse pregnancy outcomes compared with those reported correctly, which could lead to overestimation of our risk estimates.
We had detailed information on several potential confounders. There were no missing data for maternal age and parity, but 21% of pregnancies lacked smoking data. 19 We performed analyses excluding smoking as well as other potential confounders, but with only small changes in risk estimates. Previous preterm deliveries are a major independent risk factor Unauthorized reproduction of this article is prohibited.
for preterm birth. 20 Adjustment for previous preterm deliveries did not change our risk estimates (HR 1.8, 95% CI 1.6-1.9). To possibly control for potentially unrecognized risk factors, we also compared pregnancy outcome before with outcome after treatment in the same women, yielding a crude odds ratio of 2.2 for preterm birth after treatment. This did not indicate substantial unaccounted for risk factors. Copyright Ó by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
Unauthorized reproduction of this article is prohibited.
A weakness concerning the dose-response analysis of excised tissue was that cone size information was only available for 37% of treatments, and we did not have information on the possibly more descriptive measure of excision depth and length. The availability of cone size depends on the reporting practices of the individual institutions and laboratories. There were differences (P,.05) between women with and without reported cone size with regard to maternal age at delivery, screening history, and education, but not with regard to parity, marital status, smoking, and maternal country of origin. In absolute numbers, however, the differences were small. In this study, we present subgroup analyses for six different pregnancy outcomes according to seven specific treatments, which may raise concern of false-positive associations. However, we only presented results for adverse outcomes also examined in other studies.
A 2006 meta-analysis of obstetrics outcomes after treatment for cervical lesions showed that cold knife conization and LEEP were associated with increased risk of preterm delivery, low birth weight, and other outcomes. 7 In a 2008 meta-analysis, women who became pregnant after undergoing cold Copyright Ó by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
knife conization and radical diathermy had increased risk of perinatal mortality, severe preterm delivery, and extreme low-birth-weight neonates, whereas LEEP was not associated with severe obstetric morbidity. 5 In a 2011 meta-analyses, new evidence was provided that ablative treatment may also be associated with a smaller increased risk. 21 In our study, treatment with excisional procedures was associated with an increased risk of preterm delivery, and the strongest associations were seen for cold knife and laser conization. However, we also found an increased risk for LEEP. Furthermore, treatment with laser conization and LEEP was associated with an increased risk of spontaneous abortion and of stillbirth and perinatal mortality after laser conization. A Danish study showed that increasing cone depth was positively associated with preterm delivery. 8 In a recent U.K. study, the risk of preterm birth was minimally affected by small excisions, whereas larger excisions were associated with doubled risk. 12 In our study, increasing amount of tissue excised was associated with increased risk of preterm delivery, but also in the lowest weight category, there was an increased risk.
The risk of preterm delivery has been reported not to change with time from treatment to conception or delivery. 8, 12, 22 Also in our study, the excess risk of preterm birth did not change with time. When looking at time since last treatment, no substantial changes in risk estimates were seen as well.
Treated as well as untreated women with precancerous lesions have higher risk of preterm birth than the general population. 21, 23 Thus, characteristics of the women or the underlying pathologic changes themselves might increase the risk. In our study, we adjusted for several potential confounders with only minor changes in risk estimates. Restricting the analyses to those with abnormal Pap test results 3.5 years before delivery did not substantially change the strength of association. We also found no differences between CIN grade and risk of preterm birth, in accordance with other registry-based studies. 8, 22 We demonstrated that treatment before birth was associated with increased risk of spontaneous abortions. A 2014 meta-analysis on fertility and early pregnancy outcomes after CIN treatment showed that treatment increased the risk of miscarriage in the second but not the first trimester. 24 Several large cohort studies, including ours, have found increased risks of adverse pregnancy outcomes. However, the risk may depend on the treatment Unauthorized reproduction of this article is prohibited.
method, the extent of excision, and other factors manifested as temporal trends. These concerns are particularly pertinent because several screening programs are currently moving to HPV-based primary screening. 25, 26 Thus, it is important to update the estimates for the current adverse effects of treatment to inform decisions on target age groups and new screening algorithms that respect an adequate balance of benefits and harms. The health burden associated with adverse pregnancy outcomes is substantial. 20 These outcomes also constitute the main potential harms of cervical screening. Based on our findings, we believe that women should be informed about their future risk of adverse pregnancy outcomes, particularly preterm birth, after excisional treatment for cervical lesions. The treatment quality (type and depth of excision) seems to influence the risk increase. Thus, it is important to provide the least destructive but effective treatment for women of childbearing age. Primary prevention of cervical cancer and its precursor lesions by HPV vaccination will also decrease the burden of cervical treatments in the years to come.
